Letters
High cost of new drugs
Regulatory agencies should engage in drug pricing
BMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i4524 (Published 23 August 2016) Cite this as: BMJ 2016;354:i4524
- Raffaella Ravinetto, senior scientist1,
- Gianluca Gaidano, professor2
- 1Institute of Tropical Medicine, Nationalestraat 155, 2000 Antwerp, Belgium
- 2Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
- rravinetto{at}itg.be
Mazzucato argues that drug pricing policies “must be completely transparent, so that governments can negotiate for better value on behalf of their populations.”1 She also observes that the US government never exercised its right to cap prices of drugs developed through publicly funded research.2 In Europe, the European Medicines …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.